Posted by Michael Wonder on 08 Jun 2022
Allogene Therapeutics announces the FDA granted regenerative medicine advanced therapy designation to ALLO-501A for large B-cell Lymphoma
8 June 2022 - In the ALPHA trials with ALLO-501 and ALLO-501A, treatment was initiated approximately 2 days from enrollment, eliminating any need for bridging therapy.
Allogene Therapeutics today announced that the U.S. FDA granted regenerative medicine advanced therapy designation to ALLO-501A in relapsed/refractory large B-cell Lymphoma.
